
## Peter De Boer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4304990/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants. Journal of Psychopharmacology, 2018, 32, 1341-1350.	4.0	44
2	A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity. Journal of Psychopharmacology, 2018, 32, 668-677.	4.0	44
3	The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder. Translational Psychiatry, 2019, 9, 216.	4.8	41
4	The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia. Journal of Psychopharmacology, 2019, 33, 202-209.	4.0	41
5	Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-controlled, multiple ascending dose trial. Journal of Psychopharmacology, 2020, 34, 1030-1042.	4.0	32
6	Neurotrophic and inflammatory markers in bipolar disorder: A prospective study. Psychoneuroendocrinology, 2017, 84, 143-150.	2.7	18
7	Multiple daytime administration of the selective orexin-2 receptor antagonist JNJ-42847922 induces somnolence in healthy subjects without residual central effects. Journal of Psychopharmacology, 2018, 32, 1330-1340.	4.0	15
8	No evidence for differential gene expression in major depressive disorder PBMCs, but robust evidence of elevated biological ageing. Translational Psychiatry, 2021, 11, 404.	4.8	14